Work on innovative treatments for severe diseases (such as cancer) has slowed to prevent clinical-trial participants from being exposed to COVID-19. Almost two-thirds of the companies we surveyed expect their development programs to be delayed by more than three months.
To read the article, see “COVID-19 and cell and gene therapy: How to keep innovation on track,” August 18, 2020.